

1 **TITLE:** Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis
2 Treated with Elexacaftor-Tezacaftor-Ivacaftor

3
4 **WORD COUNT (MAIN TEXT): 4733**

5
6 **AUTHORS:** Seth A. Reasoner^{1*}, Rachel Bernard^{2*}, Adam Waalkes³, Kelsi Penewit³, Janessa
7 Lewis³, Andrew G. Sokolow⁴, Rebekah F. Brown⁴, Kathryn M. Edwards⁵, Stephen J. Salipante³,
8 Maria Hadjifrangiskou^{1,6,7}, Maribeth R. Nicholson^{2,7}

9
10 **AFFILIATIONS:**

11 1. Division of Molecular Pathogenesis, Department of Pathology, Microbiology & Immunology,
12 Vanderbilt University Medical Center, Nashville, TN, USA

13 2. Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Monroe
14 Carrell Junior Children's Hospital at Vanderbilt, Nashville, TN, USA

15 3. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA,
16 USA

17 4. Division of Allergy, and Immunology, and Pulmonary Medicine, Department of Pediatrics,
18 Monroe Carrell Junior Children's Hospital at Vanderbilt, Nashville, TN, USA

19 5. Division of Infectious Diseases, Department of Pediatrics, Monroe Carrell Junior Children's
20 Hospital at Vanderbilt, Nashville, Tennessee, USA

21 6. Center for Personalized Microbiology (CPMi), Vanderbilt University Medical Center, Nashville,
22 TN, USA

23 7. Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical
24 Center, Nashville, Tennessee, USA

25
26 **These authors contributed equally to this work. Authorship position was determined by relative
27 contributions made to this manuscript's completion.*

28
29
30 **Corresponding Author:**

31 Maribeth R. Nicholson, MD, MPH
32 Monroe Carell Jr. Children's Hospital at Vanderbilt
33 2200 Children's Way, Nashville, TN 37232
34 Telephone: +1 615 322 7449
35 E-mail: maribeth.r.nicholson@vumc.org

36
37
38 **RUNNING TITLE:** CF Gut Microbiome Following CFTR Modulator ELX/TEZ/IVA

39
40
41 **KEY WORDS**

42 Cystic fibrosis; CFTR modulators; microbiome; elexacaftor; ivacaftor; tezacaftor; metagenomic
43 sequencing; intestinal inflammation; antibiotic resistance; pediatric

44

45 **ABSTRACT**

46 The intestinal microbiome influences growth and disease progression in children with cystic
47 fibrosis (CF). Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA), the newest pharmaceutical
48 modulator for CF, restores function of the pathogenic mutated CFTR channel. We performed a
49 single-center longitudinal analysis of the effect of ELX/TEZ/IVA on the intestinal microbiome,
50 intestinal inflammation, and clinical parameters in children with CF. Following ELX/TEZ/IVA,
51 children with CF had significant improvements in BMI, ppFEV₁ and required fewer antibiotics for
52 respiratory infections. Intestinal microbiome diversity increased following ELX/TEZ/IVA coupled
53 with a decrease in the intestinal carriage of *Staphylococcus aureus*, the predominant respiratory
54 pathogen in children with CF. There was a reduced abundance of microbiome-encoded
55 antibiotic-resistance genes. Microbial pathways for aerobic respiration were reduced after
56 ELX/TEZ/IVA. The abundance of microbial acid tolerance genes was reduced, indicating
57 microbial adaptation to increased CFTR function. In all, this study represents the first
58 comprehensive analysis of the intestinal microbiome in children with CF receiving ELX/TEZ/IVA.

59

60

61 **IMPORTANCE**

62 Cystic fibrosis is an autosomal recessive disease with significant gastrointestinal
63 symptoms in addition to pulmonary complications. Prior work has shown that the intestinal
64 microbiome correlates with health outcomes in CF, particularly in children. Recently approved
65 treatments for CF, CFTR modulators, are anticipated to substantially improve the care of
66 patients with CF and extend their lifespans. Here, we study the intestinal microbiome of children
67 with CF before and after the CFTR modulator, ELX/TEZ/IVA. We identify promising
68 improvements in microbiome diversity, reduced measures of intestinal inflammation, and
69 reduced antibiotic resistance genes. We present specific bacterial taxa and protein groups
70 which change following ELX/TEZ/IVA. These results will inform future mechanistic studies to
71 understand the microbial improvements associated with CFTR modulator treatment. This study
72 demonstrates how the microbiome can change in response to a targeted medication that
73 corrects a genetic disease.

74

75

76

77

78

79

80 1. INTRODUCTION

81 Cystic fibrosis (CF) is an autosomal recessive disease affecting a total of 40,000 individuals in
82 the United States (1). CF is caused by mutations in the CF transmembrane conductance
83 regulator (*CFTR*) gene resulting in decreased epithelial transport of chloride and bicarbonate
84 ions. These mutations result in mucus obstruction which presents with severe multi-organ
85 dysfunction, principally affecting the airways and gastrointestinal tract (2–5). The gastrointestinal
86 complications include malnutrition, dysmotility, and hepatopancreaticobiliary disease (2).
87 Importantly, nutritional status and intestinal microbiome abnormalities in children with CF have
88 been linked to growth failure, disease progression, and risk of future lung transplantation (6–11).

89 Multiple studies have demonstrated differences in the intestinal microbiome of patients with
90 CF when compared to healthy controls (8, 12–15). The CF intestinal microbiome is notably
91 inflammatory and associated with higher rates of inflammatory bowel disease (IBD) and colon
92 cancer (16–20). In infants with CF, delayed intestinal microbiome maturation has been shown to
93 influence linear growth and immune programming (8, 21). Among the most striking differences
94 compared to healthy controls is the abundance of Proteobacteria, specifically *Escherichia coli*,
95 and concomitant decrease in Bacteroidetes in infants with CF (8, 12, 22–24). Furthermore,
96 during acute CF pulmonary exacerbations, the intestinal microbiome is distinguishable from
97 periods of respiratory stability (15, 21, 25). Respiratory pathogens, such as *Staphylococcus*
98 *aureus*, can also be detected in CF stool samples (22, 26).

99 Over the past decade, small molecule therapies which address the primary defect in the
100 CFTR protein and rescue CFTR function in select genotypes have been developed. These
101 “CFTR modulators” have dramatically changed the trajectory of CF patient care, yielding
102 remarkable improvements in lung function, growth, and projected lifespan (27). The most recent
103 CFTR modulator formulation approved for clinical care, elexacaftor-tezacaftor-ivacaftor
104 (ELX/TEZ/IVA), includes two CFTR correctors (ELX & IVA) and one CFTR potentiator (TEZ)
105 (28). The approval of ELX/TEZ/IVA is anticipated to be the most important advancement in CF
106 therapy since *CFTR* was identified over 30 years ago (27, 28).

107 Given the progressive nature of CF, initiation of therapy in early childhood is critical to stall
108 disease progression. ELX/TEZ/IVA was approved by the FDA for pediatric patients in 2019
109 (ages 12 years and older), 2021 (ages 6-11 years old), and 2023 (ages 2-5 years old). The
110 impact of ELX/TEZ/IVA on clinical outcomes and the intestinal microbiome in children with CF
111 requires targeted study. To date, studies examining the effects of CFTR modulators on the
112 intestinal microbiome have been limited by the use of single modulator formulations or small

113 cohort sizes (29–31). Importantly, no studies have characterized the effect of ELX/TEZ/IVA on
114 the intestinal microbiome of children with CF. We therefore undertook a longitudinal study to
115 identify changes in clinical outcomes and the intestinal microbiomes of pediatric patients
116 following the initiation of ELX/TEZ/IVA. To our knowledge, this study represents the first
117 comprehensive study of the highly effective CFTR modulator formulation ELX/TEZ/IVA on the
118 intestinal microbiome of children with CF.

119

120 **2. METHODS**

121 **2.1 Recruitment of Subjects**

122 Pediatric patients with a diagnosis of CF at Monroe Carell Jr. Children's Hospital at Vanderbilt
123 (MCJCHV) were recruited beginning in July 2017 with follow-up until October 2022. Patients
124 with the Phe508 CFTR mutation who were deemed eligible for ELX/TEZ/IVA by their
125 pulmonologist were eligible for this study. Patients previously treated with other CFTR
126 modulator regimens were permitted. Patients with pre-existing non-CF gastrointestinal disease
127 were excluded. A total of 39 participants were recruited (Table 1). Informed consent was
128 obtained from parental guardians, and assent was obtained from pediatric subjects in
129 accordance with institutional research ethics guidelines. This study was approved by the
130 MCJCHV Institutional Review Board (IRB # 200396). The lead investigators of this study had no
131 direct role in the patients' routine medical care. All study data were stored in a Research
132 Electronic Data Capture (REDCap) database per institutional guidelines (32).

133

134 **2.2 Study Timepoints**

135 Our analysis included stool samples from up to four timepoints per patient: two timepoints
136 before ELX treatment (T1 & T2) and two timepoints after initiating ELX/TEZ/IVA (T3 & T4) (Fig.
137 1B). For clinical outcomes, data was either analyzed by individual timepoints (T1-T4) or time
138 points were combined for pre-ELX/TEZ/IVA samples (T1 & T2 combined) and post-ELX-
139 TEZ/IVA samples (T3 & T4 combined). Analysis of individual timepoints permitted assessment
140 of additional differences between the 6 to 12-month periods after ELX/TEZ/IVA initiation. For
141 microbiome comparisons, analysis was based on combined pre-ELX/TEZ/IVA samples (T1 &
142 T2) and post-ELX-TEZ/IVA samples (T3 & T4).

143

144 **2.3 Stool Sample Collection and DNA Extraction**

145 Stool samples were collected prior to ELX/TEZ/IVA initiation, either through targeted collection
146 as part of this study or from our center's biobank of CF stool samples (33, 34). Subsequent stool

147 samples were collected at approximately 6- and 12-month intervals after initiation of
148 ELX/TEZ/IVA (Fig. 1A). Fecal samples were collected in sterile collection cups and refrigerated
149 until transport to the laboratory. Patients who were unable to provide a stool sample in clinic
150 were provided with an OMNIgene®•GUT stool collection kit for at home collection and
151 stabilization, returned via overnight shipping, and stored according to manufacturer
152 specifications. Aliquots of stool samples were aseptically aliquoted into cryovials in a laminar
153 flow biosafety cabinet to minimize aerosols and stored at -80°C until processing. Percent
154 predicted forced expiratory volume in one second (ppFEV₁) values were obtained in the
155 outpatient setting at the time of stool sample collection; the highest spirometry value of three
156 attempts was recorded. Clinical data including body mass index (BMI, percentiles), percentage
157 predicted forced expiratory volume in 1 second (ppFEV₁), medications, and laboratory values
158 were recorded for visits when a stool sample was collected. Total DNA was extracted from 114
159 stool samples using QIAamp PowerFecal Pro DNA Kits according to the manufacturer's
160 instructions. Bead beating for efficient lysis was conducted for 10 minutes. All steps, excluding
161 bead beating and centrifugation, were conducted in a laminar flow biosafety cabinet. No human
162 DNA depletion or enrichment of microbial DNA was performed. DNA yield was estimated by
163 spectrophotometry (NanoDrop™2000c) in parallel with ensuring satisfactory A260/A280 ratio for
164 DNA purity.

165

166 **2.4 Fecal Calprotectin Measurements**

167 Fecal calprotectin was measured using the Calprotectin ELISA Assay Kit (Eagle Biosciences).
168 Duplicate portions of stool (50-100mg) were weighed and processed according to the
169 manufacturer's instructions. Absorbance was measured with a SpectraMax® i3x (Molecular
170 Devices). Fecal calprotectin (µg/g feces) was calculated using a 7-point standard curve. The
171 assay's reported normal cut-off is <43.2 µg/g.

172

173 **2.5 Shotgun Metagenomic Sequencing**

174 Sequencing libraries were prepared using Illumina® reagents as described elsewhere (35).
175 Pooled libraries were sequenced on NextSeq2000 to generate 150-bp paired-end reads. An
176 average of 13.9 million reads were produced per sample (range 9.1 to 30.1 million). Sequencing
177 adaptors and low-quality sequences were trimmed with fastq-mcf from ea-utils-1.1.2.779 using
178 default parameters (Supplementary Methods) (36).

179

180 **2.6 Taxonomic and Functional Profiling of Metagenomic Sequence Data**

181 Species abundances were determined with MetaPhlan4 following read alignment to the
182 MetaPhlan4 database (37). Diversity metrics were calculated with the vegan R package (38)
183 and plotted with ggplot2. A weighted UniFrac distance matrix was constructed with the
184 MetaPhlan R script “calculate_unifrac”. Functional profiling was conducted with HUMAnN 3.0
185 with mapping to UniRef90 gene-families and MetaCyc metabolic pathways (39–41). UniRef90
186 gene-families were reformatted into KEGG orthology (KO) groups using the HUMAnN command
187 “humann_regroup_table”. In total, we identified 722 species, 526 MetaCyc pathways, and 8634
188 distinct KO groups annotations in the 114 samples. All functional annotations were normalized
189 using the HUMAnN command “humann_renorm_table --units cpm”. Antibiotic resistance genes
190 were identified by ShortBRED (42) with the reference Comprehensive Antibiotic Resistance
191 Database (CARD version 2017) (43). ARG abundance was calculated as reads per kilobase of
192 reference sequence per million sample reads (RPKM).

193

194 **2.7 Microbial Dysbiosis Index**

195 The Microbial Dysbiosis Index (MD-index) was calculated as the log₁₀ of the ratio of the relative
196 abundance of taxa which were previously positively and negatively associated with newly
197 diagnosed pediatric Crohn’s disease (44). Specifically, the numerator includes
198 *Enterobacteriaceae*, *Pasteurellaceae*, *Fusobacteriaceae*, *Neisseriaceae*, *Veillonellaceae*,
199 *Gemellaceae*; the denominator includes *Bacteroidales*, *Clostridiales* (excluding *Veillonellaceae*),
200 *Erysipelotrichaceae*, and *Bifidobacteriaceae*. Higher indices correspond to a greater
201 inflammatory taxonomic profile. The MD-index has been previously applied to stool samples of
202 children with CF (14, 45).

203

204 **2.8 Differential Abundance Testing**

205 We used MaAsLin2 (Microbiome Multivariable Associations with Linear Models, Maaslin2 R
206 package) to identify differentially abundant features (46). We included ELX/TEZ/IVA, age, and
207 recent antibiotic exposure as fixed effects. Subject ID was specified as a random effect due to
208 multiple samples from the same subject. Species, KEGG orthologs, and MetaCyc pathways
209 detected at least 10% of samples were tested (i.e., prevalence = 0.1); no minimum abundance
210 was specified. Abundances were log transformed within the MaAsLin2 function. The general
211 linear “LM” model was used. MaAsLin2 coefficients are equivalent to log₂(FoldChange). The
212 Benjamini-Hochberg procedure was used to correct P values, and corrected P values are
213 reported as False Discovery Rates (FDR).

214

215 **2.9 Statistical Analyses**

216 Statistical analyses were conducted using GraphPad Prism 9 and R (version 4.2.1) software.
217 Details of the statistical tests used and the significance thresholds are presented in the figure
218 legends. All box-plot graphs are defined as: center line—median; box limits—upper and lower
219 quartiles; whiskers—1.5× interquartile range.

221 **2.10 Reproducibility and Data Availability**

222 The results can be reproduced using raw sequence data that are available on NCBI-Genbank
223 databases under BioProject PRJNA948536 or using processed data in the Supplementary
224 Dataset 1. Bioinformatic code is available within the repository [https://github.com/reaset41/CF-](https://github.com/reaset41/CF-GI-Microbiome-ELX-TEZ-IVA)
225 [GI-Microbiome-ELX-TEZ-IVA](https://github.com/reaset41/CF-GI-Microbiome-ELX-TEZ-IVA).

227 **3. RESULTS**

228 **3.1 Study Cohort and Stool Sample Collection**

229 Stool samples were collected from a total of 39 children with CF (Table 1). The median
230 (IQR) age of participants at the time of ELX/TEZ/IVA initiation was 9.86 years old (8.87, 12.15)
231 and 53.4% were male. Of these, 35.9% (14/39 subjects) had CFTR modulator use (at any time)
232 before ELX/TEZ/IVA. Patients provided an average of 2.92 stool samples with all patients
233 providing at least one stool sample prior to starting ELX/TEZ/IVA (T1 median= 33.6 months
234 before ELX/TEZ/IVA initiation, IQR 28.6, 36.7 months and T2 median=0.64 months before
235 ELX/TEZ/IVA initiation, IQR 0.13, 2.2 months). Subsequent stool samples were collected at
236 approximately 6- and 12-month intervals (T3 median=5.97 months, IQR 5.38, 6.92 months and
237 T4 median=12.39 months, IQR 11.1, 13.1 months). There was a total of 114 stool samples with
238 53 samples before ELX/TEZ/IVA therapy and 61 samples after ELX/TEZ/IVA treatment (Fig. 1A
239 & S2). Of the 53 samples collected pre-ELX/TEZ/IVA, 8 samples (15%) were collected while the
240 patient was receiving an alternative CFTR modulator (Supplementary Dataset 1).

242 **3.2 Clinical Improvement after ELX/TEZ/IVA**

243 To determine our cohort's clinical response to ELX/TEZ/IVA, we compared clinical
244 metrics from before and after ELX/TEZ/IVA initiation. Both BMI percentile and ppFEV₁ increased
245 in the timepoints after ELX/TEZ/IVA compared to pre-ELX/TEZ/IVA timepoints (Fig. 1C-D &
246 S1A-B). Median BMI percentile increased from the 54th percentile to the 67th percentile after
247 ELX/TEZ/IVA (Fig. 1D). Likewise, there was a mean change in ppFEV₁ of 12.3 percentage
248 points (95% CI 6.7-17.8) before and after ELX/TEZ/IVA (Fig. 1C). Between 6- and 12-months

249 after ELX/TEZ/IVA, there was no further significant improvement in either BMI or ppFEV₁ (Fig.
250 S1A-B, T3 & T4). Consistent with increased BMI, weight percentile increased after ELX/TEZ/IVA
251 (Fig. S1C). Height percentile increased between T2 and both T3 and T4 (Fig. S1D, P=0.013,
252 P=0.026, respectively), though not between T1 and T3 & T4. Total antibiotic days per patient
253 were aggregated and decreased from a median of 22.5 days per 6-months before ELX/TEZ/IVA
254 to 0 antibiotic days per 6-months after ELX/TEZ/IVA (Fig. 1E, P<0.0001).

255

256 **3.3 Microbiome Diversity Increases After ELX/TEZ/IVA**

257 From shotgun metagenomic sequencing on 114 stool samples, we compared measures
258 of microbiome taxonomy and diversity. In contrast to previously published CF microbiome
259 datasets of infants (8, 22), our dataset of older children was dominated by the phylum
260 Firmicutes with minimal Proteobacteria (Fig. 2A and Supplementary Dataset 1). Alpha diversity,
261 as measured by the Shannon index and richness (observed species), significantly increased
262 following ELX/TEZ/IVA (Fig. 2B-C, P=0.021 and P=0.026, respectively). The number of species
263 observed increased from a median (IQR) of 83 (62, 115) species before ELX/TEZ/IVA to 109
264 (82,125) species after ELX/TEZ/IVA (Fig. 2B). The cumulative increases in alpha diversity were
265 not significantly different when comparing between the four timepoints individually (Fig. S2A-B),
266 and there were no differences in overall community composition (beta-diversity) before and after
267 ELX/TEZ/IVA (Fig. S2C-D).

268 To determine the effect of prior CFTR modulator treatment besides ELX/TEZ/IVA, we
269 compared diversity metrics between modulator naïve samples (samples=45) and samples
270 collected while subjects were receiving another CFTR modulator (samples=8) before
271 ELX/TEZ/IVA. Samples collected while subjects were receiving another CFTR modulator had
272 similar diversity to modulator naïve samples (Fig. S3A-B). Following ELX/TEZ/IVA, samples
273 from subjects who had previously received another modulator (samples=20) had similar
274 improvements in microbiome diversity to samples from subjects who had not previously
275 received another modulator (samples=41), indicating that the residual effects of another
276 modulator did not influence microbiome diversity improvement on ELX/TEZ/IVA (Fig. S3C-D).

277 To determine the influence of antibiotic exposure on microbiome diversity measures
278 regardless of ELX/TEZ/IVA status, we categorized patient stool samples as having received
279 antibiotics within the six-months prior to stool sample collection (samples=62) or no antibiotic
280 receipt (samples=52). Recent antibiotic exposure significantly impacted alpha diversity
281 measures reducing Shannon diversity and richness (Fig. 2D-E). Likewise, population structure

282 (beta-diversity) was significantly different between samples with and without recent antibiotic
283 exposure (Fig. S2E, permutational multivariate analysis of variance [PERMANOVA]=0.003).

284

285 **3.4 Microbiome Encoded Antibiotic Resistance Genes Decrease After ELX/TEZ/IVA**

286 As discussed above, patients required far fewer antibiotics after starting ELX/TEZ/IVA
287 (Fig. 1E & S4A). Since the intestinal microbiome is a reservoir of antibiotic resistant genes
288 (ARGs) (47), we compared the number and type of intestinal ARGs before and after
289 ELX/TEZ/IVA initiation. Across the 114 samples, we detected a total of 309 unique ARGs. The
290 median number of unique ARGs nominally decreased from a median 86 ARGs (IQR 40, 96)
291 before ELX/TEZ/IVA to a median 68 ARGs (IQR 38, 90) after ELX/TEZ/IVA (Fig. S4B, P=0.31).
292 ARG abundance decreased from a median of 1180 RPKM (IQR 815.4, 1761.1) to 829 RPKM
293 (IQR 460.5, 1299.0) (Fig. 3A, P=0.0097) though this effect was likely mediated by reduced
294 antibiotic use.

295 Next, we aggregated the relative abundance of ARGs by antibiotic class to which they
296 confer resistance (Fig. 3B). The abundance of ARGs conferring resistance to peptide antibiotics
297 and ungrouped antibiotics (“Other”) significantly decreased after ELX/TEZ/IVA (Fig. 3B & S4C-
298 E, P=0.012, P=0.022 respectively). The most prevalent antibiotics within the peptide ARG class
299 included *arnA* (samples=72/114), *yojI* (samples=71/114), *pmrF* (samples=74/114) and *pmrC*
300 (samples=71/114). *arnA*, *pmrF* and *pmrC* modify Lipid A on bacterial cells to repel cationic
301 peptide antibiotics, whereas *yojI* is a peptide efflux pump. The most prevalent ARGs within the
302 “Other” group were *fabI* (samples=84/114), *gadE* (samples=78/114), and EF-Tu mutations
303 (samples=75/114). These ARGs or mutations confer resistance to isoniazid/disinfecting agents
304 (*fabI*), acid resistance and efflux pump (*gadE*), and elfamycin (EF-Tu). Despite being the most
305 prevalent, none of these ARGs were independently altered in abundance following
306 ELX/TEZ/IVA (Fig. S4D & S4F).

307

308 **3.5 Alterations to Specific Bacterial Taxa Following ELX/TEZ/IVA**

309 To determine whether specific bacterial taxa change following ELX/TEZ/IVA treatment,
310 we used MaAsLin2 (Microbiome Multivariable Associations with Linear Models) to identify
311 differentially abundant microbial taxa (46). No phyla were differentially abundant following
312 ELX/TEZ/IVA (Fig. 2A & Table S4). At a granular taxonomic level, seventeen species were
313 differentially abundant between samples before and after ELX/TEZ/IVA (FDR<0.1, Fig. 4A and
314 Table S3), with eleven species increasing in abundance after ELX/TEZ/IVA, and six species
315 decreasing. The three species with the lowest FDR and, therefore, highest reliability were

316 *Butyricoccus* SGB14985, *S. aureus*, and *Roseburia faecis* (Fig. 4A-B). *Butyricoccus*
317 SGB14985, an uncultivated species, was decreased in abundance following ELX/TEZ/IVA (fold
318 change 0.16, FDR=0.022). *Roseburia faecis* was increased in abundance following
319 ELX/TEZ/IVA (fold change 7.35, FDR=0.025) and negatively correlated with recent antibiotic
320 exposure (Fig. S5A, fold change 0.20, FDR=0.086). The intestinal tract has immunological
321 cross-talk between the separate but similarly structured mucosal environment of the lung,
322 deemed the gut-lung axis (20). Since the intestinal tract can harbor similar respiratory
323 pathogens in patients with CF (15, 48, 49), we performed focused analysis of CF pathogens. *S.*
324 *aureus*, the predominant respiratory pathogen in children with CF (50), was decreased in
325 abundance after ELX/TEZ/IVA (Fig. 4A-B, fold change 0.40, FDR=0.042). Other members of the
326 respiratory microbiota which are frequently detected in the intestines (14, 15)—specifically the
327 genera *Haemophilus*, *Prevotella*, *Streptococcus*, *Veillonella*—did not significantly change after
328 ELX/TEZ/IVA initiation (Fig. S5B). *Pseudomonas aeruginosa*, an additional respiratory pathogen
329 of importance in CF, was detected in only two of the 114 stool samples. Furthermore, fungal
330 taxa were only identified in 8/114 samples (Supplementary Dataset 1).

331

332 **3.6 Intestinal Inflammation Decreases After ELX/TEZ/IVA**

333 Fecal calprotectin was measured across the four timepoints and markedly decreased
334 following ELX/TEZ/IVA (Fig. 5A & S5A). Overall, mean fecal calprotectin decreased from 109
335 $\mu\text{g/g}$ before ELX/TEZ/IVA to 44.8 $\mu\text{g/g}$ for a mean decrease of 64.2 $\mu\text{g/g}$ (95% CI -16.1, -112.3,
336 Fig. 5A). We then computed the microbial dysbiosis index (MD-index), a ratio of bacterial taxa
337 positively and negatively associated with newly diagnosed pediatric Crohn's disease, to assess
338 the relationship between intestinal inflammation and specific microbial signatures (44). We
339 noted a nominal reduction in the MD-index following ELX/TEZ/IVA (Fig. 5B, $P=0.068$), which
340 was less pronounced when comparing samples from patients with recent antibiotic exposure
341 and those without (Fig. 5C, $P=0.77$).

342

343 **3.7 Microbiome Functional Changes Reveal Specific Disease-Relevant Changes**

344 From the 114 stool samples, alignment of sequencing reads to known microbial proteins and
345 pathways identified 8634 KEGG orthology (KO) protein groups and 526 MetaCyc metabolic
346 pathways, consistent with prior studies of the intestinal microbiota (51). There were 249 KO
347 groups differentially abundant with respect to ELX/TEZ/IVA use (MaAsLin2 FDR<0.25, Fig. 5D
348 & Table S6). Strikingly, a common thread among differentially abundant KO groups was a
349 decreased abundance of genes encoding oxidative phosphorylation functions following

350 ELX/TEZ/IVA (Fig. 5D). Seven of the top 10 most differentially abundant KO groups were
351 components of the electron transport chain (Fig. 5D & S5B and Table S7) and included NADH-
352 ubiquinone oxidoreductases (e.g., K03883, K03881, K03884, & K03880), F-type ATPase
353 subunits (e.g., K02125), and cytochrome c oxidase subunits (e.g., K02262, K02261, & K02256).
354 The taxa contributing to oxidative phosphorylation KO groups were not consistently annotated
355 by HUMAnN (Fig. S6C and Table S10). This indicates that a specific taxonomic signature was
356 not responsible for the reduced abundance of oxidative phosphorylation KO groups (Fig. S6C).
357 These results were corroborated by MaAsLin2 differential abundance testing of MetaCyc
358 pathways. Sixty-four MetaCyc pathways were differentially abundant with respect to
359 ELX/TEZ/IVA use (MaAsLin2 FDR<0.25, Fig. 5E & S7, Table S9). Two of these pathways
360 corresponded to aerobic respiration (PWY-3781 and PWY-7279). Differential abundance of
361 anaerobic energy metabolism pathways showed discordant results with one pathway increased
362 in abundance following ELX/TEZ/IVA (PWY-7383), and two pathways decreased in abundance
363 (PWY-7389 and PWY-7384) following ELX/TEZ/IVA (Fig. S7 and Table S9). Thirteen amino
364 acid biosynthesis pathways were universally prevalent in all stool samples (114/114) and
365 significantly increased in abundance following ELX/TEZ/IVA (Fig. 5E and Table S9, FDR<0.25).
366 This indicates increased biosynthetic capacity of the intestinal microbiome following
367 ELX/TEZ/IVA.

368 Furthermore, multiple pathways related to nucleobase and nucleotide metabolism were
369 differentially abundant following ELX/TEZ/IVA. Pyrimidine deoxyribonucleotide biosynthesis
370 pathways were reduced in abundance following ELX/TEZ/IVA (PWY-7184 & PWY-6545)
371 whereas a pyrimidine ribonucleotides biosynthesis pathway was increased in abundance
372 (PWY0-162, Fig.S7 and Table S9). While these general pyrimidine deoxyribonucleotide
373 biosynthesis pathways were reduced in abundance, specific pathways for thiamine biosynthesis
374 (PWY-7357) and two uridine-monophosphate biosynthesis pathways (PWY-7790 & PWY-7791)
375 were significantly increased in abundance following ELX/TEZ/IVA. An anaerobic pathway for
376 purine degradation was increased in abundance following ELX/TEZ/IVA (P164-PWY). Three
377 pathways related to allantoin degradation were significantly reduced in abundance following
378 ELX/TEZ/IVA (PWY-5692, PWY0-41 & URDEGR-PWY, Fig. S7 and Table S9).

379 Another intriguing observation was the reduced abundance of KO groups involved in acid
380 tolerance and transport following ELX/TEZ/IVA (Fig. 5D). KO groups involved in organic acid
381 transport (e.g., K03290 & K23016) and proton-symporters (e.g., K11102 & K03459) were
382 reduced in abundance following ELX/TEZ/IVA. Likewise, an acidity-responsive transcriptional

383 regulator (K03765, *cadC*) was decreased in abundance following ELX/TEZ/IVA (Fig. 5D and
384 Table S7, fold change 0.42, FDR=0.27).

385

386 4. DISCUSSION

387 ELX/TEZ/IVA has changed the trajectory of CF patient care and dramatically improved
388 clinical outcomes. Nutritional status and components of the intestinal microbiome are strong
389 predictors of future clinical outcomes, particularly in children with CF (6–8). We therefore sought
390 to determine the effects of ELX/TEZ/IVA on intestinal inflammation and the intestinal
391 microbiome in children with CF. Herein, we present a comprehensive longitudinal
392 characterization of the intestinal microbiome in children with CF treated with ELX/TEZ/IVA. We
393 identified widespread changes to the intestinal microbiome after ELX/TEZ/IVA including
394 taxonomic composition, reduced carriage of ARGs, and altered microbiota metabolic functions.

395 Although randomized controlled trials demonstrated that ELX/TEZ/IVA was safe and
396 effective, there are limited post-approval clinical data, particularly in children over two years old
397 (52–56). BMI and ppFEV₁ are useful markers of clinical response to CFTR modulator treatment
398 in children (57). Our cohort demonstrated significant improvement in ppFEV₁ and BMI percentile
399 within six-months of starting ELX/TEZ/IVA, with no additional differences at later time points
400 (Fig. S1A-B). This is consistent with prior clinical trial and real-world data showing the greatest
401 impact on nutritional status and anthropometric parameters immediately after ELX/TEX/IVA
402 therapy initiation with subsequent plateau without regression in children (52, 56, 58). Prior
403 baseline BMI, particularly underweight status, has been predicted to be a major determinant of
404 increase in weight gain in patients with CF treated with ELX/TEZ/IVA (59). Furthermore,
405 between the timepoint immediately before ELX/TEZ/IVA initiation (T2) and post-ELX/TEZ/IVA
406 timepoints (T3 & T4), there was a significant increase in height percentile (Fig. S1D). This
407 suggests that CFTR modulator therapy may improve linear growth in children with CF. In sum,
408 these results support the clinical responsiveness of children with CF to ELX/TEZ/IVA.

409 The gastrointestinal microbiome influences whole-body physiology. CF intestinal
410 microbiome abnormalities begin in infancy, diverging from healthy controls soon after birth (8,
411 14, 15, 21–23). Intriguingly, the microbiome of patients with CF resembles that of patients with
412 IBD, a group with a characteristically perturbed intestinal microbiome (12, 45, 60). Considerable
413 prior research has characterized the development of the CF intestinal microbiome in infants (8,
414 13–15, 21–23). Less information exists about the CF intestinal microbiome in children and
415 adolescents (13, 24, 26, 61–65). A consistent finding is that high levels of the phylum
416 Proteobacteria, specifically the species *Escherichia coli*, define the infant CF intestinal

417 microbiome (12, 22). The abundance of Proteobacteria decreases with age in young children
418 with CF (14, 22). In our dataset of older children with CF, Proteobacteria comprised a minority of
419 the identified bacteria (Fig. 2A). In turn, the relative abundance of the phylum Firmicutes is
420 increased in our cohort, likely representing a more stable “adult-like” microbiome.

421 Direct comparison of our results to studies containing healthy controls is difficult given
422 different sampling and sequencing methodologies. Notably, although our study identified subtle
423 changes in the intestinal microbiome after initiation of ELX/TEZ/IVA in children with CF, the
424 post-ELX/TEZ/IVA intestinal microbiome remains significantly altered from what has been
425 described in healthy children. Compared to healthy children, the intestinal microbiome of
426 children with CF is delayed in development and exhibits decreased microbial diversity relative to
427 healthy controls throughout childhood and adolescence (22, 24, 63). Among the most consistent
428 differences between healthy controls and patients with CF is reduced abundance of the phylum
429 Bacteroidetes in patients with CF (13, 20, 61, 63, 66). In our dataset, Bacteroidetes remained
430 depleted post-ELX/TEZ/IVA (Fig. 2A and Table S4). Likewise, Shannon diversity remained
431 below that of similarly-aged healthy controls (24, 63), as discussed henceforth.

432 In our cohort, alpha diversity, as measured by the Shannon index and richness (observed
433 species), significantly increased following ELX/TEZ/IVA (Fig. 2B-C). These results demonstrate
434 modest but statistically significant differences in an older cohort of children with CF, whose
435 microbiome resembles that of more of a stable “adult-like” microbiome. The difference in the
436 median Shannon diversity was increased 0.29 after ELX/TEZ/IVA (Fig. 2B). In contrast, a
437 similarly aged cohort of children with CF exhibited a median ~1.0 reduced Shannon index
438 compared to healthy controls in the same study (24). Thus, while our cohort exhibited significant
439 increases in Shannon diversity, it is unlikely that this magnitude of increase restores the
440 diversity to that of similarly aged healthy controls. This is consistent with the notion that “adult-
441 like” intestinal microbiota are remarkably stable and resilient to intervention (67–69). As CFTR
442 modulator formulations are approved for younger children, particularly infants for whom the
443 microbiome is still developing, studying the effects of CFTR modulators on the developing
444 intestinal microbiome will be an important research endeavor and may show more substantial
445 differences.

446 In children with CF, markers of intestinal inflammation correlate with growth failure (11, 24).
447 Moreover, intestinal inflammation in patients with CF is linked to higher rates of IBD and
448 colorectal cancer in patients with CF (16, 17, 70). Fecal calprotectin, a laboratory marker of
449 intestinal inflammation (71–73), significantly decreased following ELX/TEZ/IVA (Fig. 5A),
450 corroborating prior reports in the PROMISE and RECOVER cohorts (74, 75). Using a dysbiosis

451 index of bacterial taxa correlated with pediatric Crohn's disease (44), we identified that this
452 dysbiosis index nominally decreased following ELX/TEZ/IVA initiation (Fig. 5B). The decrease in
453 the median MD-index was 0.166 before and after ELX/TEZ/IVA. The median post-ELX/TEZ/IVA
454 MD-index was lower (i.e. reduced inflammatory taxa) than that of healthy controls in the original
455 publication describing the MD-index (44). This suggests that the magnitude of decrease in the
456 MD-index in our study may be biologically meaningful. Furthermore, the difference between pre-
457 and post-ELX/TEZ/IVA (Fig. 5B) was more pronounced than in samples with and without recent
458 antibiotic exposure (Fig. 5C). This suggests that this effect may be specific to ELX/TEZ/IVA
459 treatment, and not due to reduced antibiotic use. At the species level, the butyrate-producing
460 species *Roseburia faecis* was significantly enriched following ELX/TEZ/IVA (Fig. 4A-B). Prior
461 studies have identified *R. faecis* as reduced in abundance in patients with CF (20, 76–78). In
462 parallel, we detected reduced abundance of genes involved in oxygen-dependent metabolism
463 following ELX/TEZ/IVA (Fig. 5D-E). Intestinal inflammation is characterized by a shift towards
464 oxygen-dependent microbiota metabolism, perpetuating a cycle of inflammatory damage (79–
465 81). From multiple lines of evidence, our results suggest that ELX/TEZ/IVA reduces intestinal
466 inflammation in children with CF.

467 Respiratory infections require frequent antibiotics in patients with CF. Some respiratory
468 pathogens also colonize the intestinal tract and temporally correlate with respiratory colonization
469 (15, 48, 49). *S. aureus* is among the first pathogens to colonize the respiratory tract and cause
470 infections in children with CF (50). We detected reduced intestinal abundance of *S. aureus*
471 following ELX/TEZ/IVA (Fig. 4A-B). Antibiotic exposure in patients with CF has been associated
472 with increased intestinal carriage of antibiotic resistant bacteria compared to healthy controls
473 which are a poor prognostic factor (82–84). Following ELX/TEZ/IVA, patients in our cohort
474 required far fewer antibiotics (Fig. 1E). In turn, we detected reduced intestinal abundance of
475 ARGs (Fig. 2E). These results indicate disease-relevant taxonomic changes to the intestinal
476 microbiome following ELX/TEZ/IVA, as well as reduced ARGs.

477 The CFTR channel permits transepithelial movement of bicarbonate (HCO_3^-) and
478 chloride (Cl^-) (5). Intestinal pH is lower in patients with CF due to the lack of neutralizing
479 bicarbonate (85) yet increases with CFTR modulator treatment, consistent with increased CFTR
480 activity in the intestinal tract (86). We observed a reduced abundance of microbial protein
481 groups associated with acid tolerance (Fig. 5D), consistent with microbial adaptation to
482 increased CFTR channel function in the intestines. These results display physiologically intuitive
483 functional changes to the microbiome post-ELX/TEZ/IVA. As CFTR modulators become the

484 mainstay of treatment for CF, further research will be necessary to mechanistically describe the
485 effects of CFTR modulators on gastrointestinal function.

486 Our study is strengthened by longitudinal sampling over a five-year period combined
487 with the real-world use of ELX/TEZ/IVA. Using shotgun metagenomic sequencing, we
488 comprehensively compared microbiota differences before and after ELX/TEZ/IVA. Sampling of
489 the intestinal microbiome over extended periods will be important to uncover additional long-
490 term improvements to the microbiome. Similarly, further research is necessary to delineate the
491 effects of ELX/TEZ/IVA on the interconnected respiratory and intestinal microbiomes. Although
492 our study was limited by the single-center focus, our cohort mirrors the overall CF pediatric
493 population in clinical and demographic factors (Table 1). Our study lacks untreated CF controls
494 or healthy controls, which would allow for additional comparisons.

495 In summary, our results indicate that the CFTR modulator ELX/TEZ/IVA alters the
496 intestinal microbiome in children with CF. We identified taxonomic and functional changes to the
497 intestinal microbiome that represent improvements to CF intestinal microbiome structure and
498 function. Our results also support that CFTR modulators reduce intestinal inflammation in
499 children with CF.

500

501 **AUTHOR CONTRIBUTIONS (CRediT author statement)**

502 SAR: Investigation, Methodology, Data Curation, Formal analysis, Writing - Original Draft

503 RB: Conceptualization, Funding Acquisition, Investigation, Data Curation, Writing - Original Draft

504 AW: Investigation, Software

505 KP: Investigation

506 JS: Investigation

507 AGS: Supervision, Writing - Review & Editing

508 RFB: Supervision, Writing - Review & Editing

509 KME: Supervision, Writing - Review & Editing

510 SJS: Investigation, Data Curation, Software, Writing - Review & Editing

511 MH: Supervision, Writing - Review & Editing

512 MRN: Conceptualization, Funding Acquisition, Investigation, Supervision, Writing - Original Draft

513

514 **ACKNOWLEDGEMENTS AND FUNDING**

515 We would like to express our sincere appreciation to the patients and their families who

516 enthusiastically participated in this study. We would like to thank our advanced practitioner and

517 nursing colleagues from the Pediatric Pulmonology clinic at the Monroe Carrell Jr. Children's

518 Hospital at Vanderbilt for their collegiality and assistance with this study. This work was
519 supported, in part, by National Institutes of Health (NIH) grants T32DK007673 (RB),
520 K23AI156132 (MRN), F30AI169748 (SAR), T32GM007347 (SAR), and P30DK089507 (SJS);
521 the Cystic Fibrosis Foundation (SINGH19R0 to SJS) and the Thrasher Research Fund (RB and
522 MRN).

523

524 **CONFLICTS OF INTERESTS**

525 All authors declare that they have no conflicts of interest relevant to this work.

526

527 **DATA AVAILABILITY**

528 All sequence data derived from this work are publicly available in NCBI-Genbank databases
529 under BioProject PRJNA948536. All processed data and code used for bioinformatic analysis is
530 available within the repository: <https://github.com/reaset41/CF-GI-Microbiome-ELX-TEZ-IVA>.

531

532 **AUTHOR ORCID IDs:**

533 SAR: 0000-0002-7791-1641

534 RB: 0000-0002-6689-5658

535 AW: 0000-0002-5202-1108

536 KP: 0000-0003-1454-6381

537 AGS: 0000-0002-5495-1237

538 RFB: 0000-0003-3632-4587

539 KME: 0000-0003-3912-9832

540 SJS: 0000-0001-8355-6992

541 MH: 0000-0003-4249-8997

542 MRN: 0000-0003-3941-5599

543

544 **REFERENCES**

- 545 1. 2022. CF Foundation Estimates Increase in CF Population. Cystic Fibrosis Foundation.
546 <https://www.cff.org/news/2022-07/cf-foundation-estimates-increase-cf-population>.
547 Retrieved 10 April 2023.
- 548 2. Moshiree B, Freeman AJ, Vu PT, Khan U, Ufret-Vincenty C, Heltshe SL, Goss CH,
549 Schwarzenberg SJ, Freedman SD, Borowitz D, Sathe M. 2022. Multicenter prospective
550 study showing a high gastrointestinal symptom burden in cystic fibrosis. *Journal of Cystic*
551 *Fibrosis* <https://doi.org/10.1016/j.jcf.2022.10.006>.
- 552 3. De Lisle RC, Borowitz D. 2013. The cystic fibrosis intestine. *Cold Spring Harb Perspect*
553 *Med* 3:1–18.
- 554 4. Kreda SM, Davis CW, Rose MC. 2012. CFTR, mucins, and mucus obstruction in cystic
555 fibrosis. *Cold Spring Harb Perspect Med* 2.
- 556 5. Elborn JS. 2016. Cystic fibrosis. *The Lancet* 388:2519–2531.

- 557 6. Steinkamp G, Wiedemann B. 2002. Relationship between nutritional status and lung
558 function in cystic fibrosis: Cross sectional and longitudinal analyses from the German CF
559 quality assurance (CFQA) project. *Thorax* 57:596–601.
- 560 7. Ashkenazi M, Nathan N, Sarouk I, Aluma BEB, Dagan A, Bezalel Y, Keler S, Vilozni D,
561 Efrati O. 2019. Nutritional Status in Childhood as a Prognostic Factor in Patients with
562 Cystic Fibrosis. *Lung* <https://doi.org/10.1007/s00408-019-00218-3>.
- 563 8. Hayden HS, Eng A, Pope CE, Brittnacher MJ, Vo AT, Weiss EJ, Hager KR, Martin BD,
564 Leung DH, Heltshe SL, Borenstein E, Miller SI, Hoffman LR. 2020. Fecal dysbiosis in
565 infants with cystic fibrosis is associated with early linear growth failure. *Nat Med* 26:215–
566 221.
- 567 9. Rogers GB, Carroll MP, Hoffman LR, Walker AW, Fine DA, Bruce KD. 2010.
568 Comparing the microbiota of the cystic fibrosis lung and human gut. *Gut Microbes* 1:85–
569 93.
- 570 10. Héry-arnaud G, Boutin S, Cuthbertson L, Elborn SJ, Tunney MM. 2019. The lung and gut
571 microbiome: what has to be taken into consideration for cystic fibrosis? *Journal of*
572 *Cystic Fibrosis* 18:13–21.
- 573 11. Dhaliwal J, Leach S, Katz T, Nahidi L, Pang T, Lee JM, Strachan R, Day AS, Jaffe A, Ooi
574 CY. 2015. Intestinal inflammation and impact on growth in children with cystic fibrosis. *J*
575 *Pediatr Gastroenterol Nutr* 60:521–526.
- 576 12. Hoffman LR, Pope CE, Hayden HS, Heltshe S, Levy R, McNamara S, Jacobs MA,
577 Rohmer L, Radey M, Ramsey BW, Brittnacher MJ, Borenstein E, Miller SI. 2014.
578 *Escherichia coli* dysbiosis correlates with gastrointestinal dysfunction in children with
579 cystic fibrosis. *Clinical Infectious Diseases* 58:396–399.
- 580 13. Manor O, Levy R, Pope CE, Hayden HS, Brittnacher MJ, Carr R, Radey MC, Hager KR,
581 Heltshe SL, Ramsey BW, Miller SI, Hoffman LR, Borenstein E. 2016. Metagenomic
582 evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of
583 children with cystic fibrosis. *Sci Rep* 6:1–9.
- 584 14. Price CE, Hampton TH, Valls RA, Barrack KE, O’Toole GA, Madan JC, Coker MO.
585 2023. Development of the intestinal microbiome in cystic fibrosis in early life. *mSphere*
586 <https://doi.org/10.1128/msphere.00046-23>.
- 587 15. Madan JC, Koestle DC, Stanton BA, Davidson L, Moulton LA, Housman ML, Moore JH,
588 Guill MF, Morrison HG, Sogin ML, Hampton TH, Karagas MR, Palumbo PE, Foster JA,
589 Hibberd PL, O’Toole GA. 2012. Serial analysis of the gut and respiratory microbiome in
590 cystic fibrosis in infancy: Interaction between intestinal and respiratory tracts and impact
591 of nutritional exposures. *mBio* 3.
- 592 16. Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB,
593 Braid AL, Cullina J, Daggett A, Fink A, Gini A, Harron PF, Lansdorp-Vogelaar I,
594 Lieberman D, Liou T, Lomas P, Marshall B, Meyer K, Rustgi A, Shaikat A, Sabadosa K.
595 2018. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations.
596 *Gastroenterology* 154:736-745.e14.
- 597 17. Hegagi M, Aaron SD, James P, Goel R, Chatterjee A. 2017. Increased prevalence of
598 colonic adenomas in patients with cystic fibrosis. *Journal of Cystic Fibrosis* 16:759–762.
- 599 18. Schwarzenberg SJ, Wielinski CL, Shamieh I, Carpenter BLM, Jessurun J, Weisdorf SA,
600 Warwick WJ, Sharp HL. 1995. Cystic fibrosis-associated colitis and fibrosing
601 colonopathy. *J Pediatr* 127:565–570.

- 602 19. Burton S, Hachem C, Abraham J. 2021. Luminal Gastrointestinal Manifestations of Cystic
603 Fibrosis. *Curr Gastroenterol Rep* 23.
- 604 20. Price CE, O'Toole GA. 2021. The gut-lung axis in cystic Fibrosis. *J Bacteriol. American*
605 *Society for Microbiology* <https://doi.org/10.1128/JB.00311-21>.
- 606 21. Antosca KM, Chernikova DA, Ruoff KL, Li K, Guill MF, MacKenzie TA, Dorman DB,
607 Moulton LA, Williams MA, Aldrich BJ, Yuan IH, Karagas MR, O'Toole GA, Madan JC.
608 2019. Altered Stool Microbiota of Infants with Cystic Fibrosis Shows Reduction in
609 Genera Associated with Immune Programming. *J Bacteriol* 201:1–15.
- 610 22. Salerno P, Verster AJ, Valls RA, Barrack KE, Price CE, Madan JC, O'Toole GA, Ross
611 BD. 2023. Persistent delay in maturation of the developing gut microbiota in infants with
612 cystic fibrosis. *bioRxiv* <https://doi.org/10.1101/2023.05.02.539134>.
- 613 23. Kristensen M, Prevaes SMPJ, Kalkman G, Tramper-Stranders GA, Hasrat R, de Winter-
614 de Groot KM, Janssens HM, Tiddens HA, van Westreenen M, Sanders EAM, Arets B,
615 Keijser B, van der Ent CK, Bogaert D. 2020. Development of the gut microbiota in early
616 life: The impact of cystic fibrosis and antibiotic treatment. *Journal of Cystic Fibrosis*
617 19:553–561.
- 618 24. Coffey MJ, Nielsen S, Wemheuer B, Kaakoush NO, Garg M, Needham B, Pickford R, Ja
619 A, Thomas T, Chee Y. Ooi. 2019. Gut Microbiota in Children With Cystic Fibrosis: A
620 Taxonomic and Functional Dysbiosis. *Sci Rep* 9:1–14.
- 621 25. Hoen AG, Li J, Moulton LA, O'Toole GA, Housman ML, Koestler DC, Guill MF, Moore
622 JH, Hibberd PL, Morrison HG, Sogin ML, Karagas MR, Madan JC. 2015. Associations
623 between gut microbial colonization in early life and respiratory outcomes in cystic
624 fibrosis. *Journal of Pediatrics* 167:138-147.e3.
- 625 26. Vernocchi P, Chierico F Del, Russo A, Majo F, Rossitto M, Valerio M, Casadei L, Storia
626 A La, De Filippis F, Rizzo C, Manetti C, Paci P, Ercolini D, Marini F, Fiscarelli EV,
627 Dallapiccola B, Lucidi V, Miccheli A, Putignani L. 2018. Gut microbiota signatures in
628 cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype. *PLoS*
629 *One* 13:1–23.
- 630 27. Mahase E. 2019. Cystic fibrosis: Triple therapy shows promising results. *The BMJ*
631 367:6347.
- 632 28. Collins FS. 2019. Realizing the Dream of Molecularly Targeted Therapies for Cystic
633 Fibrosis. *New England Journal of Medicine* 381:1862–1863.
- 634 29. Ooi CY, Syed SA, Rossi L, Garg M, Needham B, Avolio J, Young K, Surette MG,
635 Gonska T. 2018. Impact of CFTR modulation with Ivacaftor on Gut Microbiota and
636 Intestinal Inflammation. *Sci Rep* 8:1–8.
- 637 30. Ronan NJ, Einarsson GG, Deane J, Fouhy F, Rea M, Hill C, Shanahan F. 2022.
638 Modulation , microbiota and inflammation in the adult CF gut: A prospective study.
639 *Journal of Cystic Fibrosis* <https://doi.org/10.1016/j.jcf.2022.06.002>.
- 640 31. Pope CE, Vo AT, Hayden HS, Weiss EJ, Durfey S, Mcnamara S, Ratjen A, Grogan B,
641 Carter S, Nay L, Parsek M, Singh P, McKone E, Aitken M, Rosenfeld M, Hoffman L.
642 2020. Changes in fecal microbiota with CFTR modulator therapy: A pilot study. *Journal*
643 *of Cystic Fibrosis* <https://doi.org/10.1016/j.jcf.2020.12.002>.
- 644 32. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research
645 electronic data capture (REDCap)-A metadata-driven methodology and workflow process
646 for providing translational research informatics support. *J Biomed Inform* 42:377–381.

- 647 33. Reasoner SA, Fazili IF, Bernard R, Parnell JM, Sokolow AG, Thomsen KF, Edwards KM,
648 Brown RF, Nicholson MR. 2022. Prevalence, Risk Factors, and Sequelae of
649 Asymptomatic *Clostridioides difficile* Colonization in Children with Cystic Fibrosis.
650 *Journal of Cystic Fibrosis* <https://doi.org/10.1016/j.jcf.2022.12.014>.
- 651 34. Parnell JM, Fazili I, Bloch SC, Lacy DB, Garcia-Lopez VA, Bernard R, Skaar EP,
652 Edwards KM, Nicholson MR. 2021. Two-step Testing for *Clostridioides Difficile* is
653 Inadequate in Differentiating Infection From Colonization in Children. *J Pediatr*
654 *Gastroenterol Nutr* 72:378–383.
- 655 35. Gaio D, Anantanawat K, To J, Liu M, Monahan L, Darling AE. 2022. Hackflex: Low-
656 cost, high-throughput, Illumina Nextera Flex library construction. *Microb Genom* 8.
- 657 36. Aronesty E. 2011. ea-utils: Command-line tools for processing biological sequencing data.
658 <https://github.com/ExpressionAnalysis/ea-utils>.
- 659 37. Blanco-Míguez A, Beghini F, Cumbo F, McIver LJ, Thompson KN, Zolfo M, Manghi P,
660 Dubois L, Huang KD, Thomas AM, Nickols WA, Piccinno G, Piperni E, Punčochář M,
661 Valles-Colomer M, Tett A, Giordano F, Davies R, Wolf J, Berry SE, Spector TD,
662 Franzosa EA, Pasolli E, Asnicar F, Huttenhower C, Segata N. 2023. Extending and
663 improving metagenomic taxonomic profiling with uncharacterized species using
664 *MetaPhlAn 4*. *Nat Biotechnol* <https://doi.org/10.1038/s41587-023-01688-w>.
- 665 38. Dixon P. 2003. VEGAN, A Package of R Functions for Community Ecology. *Journal of*
666 *Vegetation Science* 14:927–930.
- 667 39. Franzosa EA, McIver LJ, Rahnavaard G, Thompson LR, Schirmer M, Weingart G, Lipson
668 KS, Knight R, Caporaso JG, Segata N, Huttenhower C. 2018. Species-level functional
669 profiling of metagenomes and metatranscriptomes. *Nat Methods* 15:962–968.
- 670 40. Caspi R, Billington R, Keseler IM, Kothari A, Krummenacker M, Midford PE, Ong WK,
671 Paley S, Subhraveti P, Karp PD. 2020. The MetaCyc database of metabolic pathways and
672 enzymes—a 2019 update. *Nucleic Acids Res* 48:D455–D453.
- 673 41. Abubucker S, Segata N, Goll J, Schubert AM, Izard J, Cantarel BL, Rodriguez-Mueller B,
674 Zucker J, Thiagarajan M, Henrissat B, White O, Kelley ST, Methé B, Schloss PD, Gevers
675 D, Mitreva M, Huttenhower C. 2012. Metabolic reconstruction for metagenomic data and
676 its application to the human microbiome. *PLoS Comput Biol* 8.
- 677 42. Kaminski J, Gibson MK, Franzosa EA, Segata N, Dantas G, Huttenhower C. 2015. High-
678 Specificity Targeted Functional Profiling in Microbial Communities with ShortBRED.
679 *PLoS Comput Biol* 11.
- 680 43. Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, Lago BA, Dave BM,
681 Pereira S, Sharma AN, Doshi S, Courtot M, Lo R, Williams LE, Frye JG, Elsayegh T,
682 Sardar D, Westman EL, Pawlowski AC, Johnson TA, Brinkman FSL, Wright GD,
683 McArthur AG. 2017. CARD 2017: Expansion and model-centric curation of the
684 comprehensive antibiotic resistance database. *Nucleic Acids Res* 45:D566–D573.
- 685 44. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B,
686 Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, González
687 A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M,
688 Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams
689 J, Huttenhower C, Knight R, Xavier RJ. 2014. The treatment-naive microbiome in new-
690 onset Crohn’s disease. *Cell Host Microbe* 15:382–392.
- 691 45. Enaud R, Hooks KB, Barre A, Barnetche T, Hubert C, Massot M, Bazin T, Clouzeau H,
692 Bui S, Fayon M, Berger P, Lehours P, Bébéar C, Nikolski M, Lamireau T, Delhaes L,

- 693 Schaefferbeke T. 2019. Intestinal Inflammation in Children with Cystic Fibrosis Is
694 Associated with Crohn’s-Like Microbiota Disturbances. *J Clin Med* 8:645.
- 695 46. Mallick H, Rahnavard A, McIver LJ, Ma S, Zhang Y, Nguyen LH, Tickle TL, Weingart
696 G, Ren B, Schwager EH, Chatterjee S, Thompson KN, Wilkinson JE, Subramanian A, Lu
697 Y, Waldron L, Paulson JN, Franzosa EA, Bravo HC, Huttenhower C. 2021. Multivariable
698 association discovery in population-scale meta-omics studies. *PLoS Comput Biol* 17.
- 699 47. Salyers AA, Gupta A, Wang Y. 2004. Human intestinal bacteria as reservoirs for
700 antibiotic resistance genes. *Trends Microbiol* <https://doi.org/10.1016/j.tim.2004.07.004>.
- 701 48. Wheatley RM, Caballero JD, van der Schalk TE, De Winter FHR, Shaw LP, Kapel N,
702 Recanatini C, Timbermont L, Kluytmans J, Esser M, Lacombe A, Prat-Aymerich C, Oliver
703 A, Kumar-Singh S, Malhotra-Kumar S, Craig MacLean R. 2022. Gut to lung translocation
704 and antibiotic mediated selection shape the dynamics of *Pseudomonas aeruginosa* in an
705 ICU patient. *Nat Commun* 13:6523.
- 706 49. Rogers GB, Carroll MP, Hoffman LR, Walker AW, Fine DA, Bruce KD. 2010.
707 Comparing the microbiota of the cystic fibrosis lung and human gut. *Gut Microbes* 1:85–
708 93.
- 709 50. Green HD, Jones AM. 2022. Managing Pulmonary Infection in Adults With Cystic
710 Fibrosis: Adult Cystic Fibrosis Series. *Chest*. Elsevier Inc.
711 <https://doi.org/10.1016/j.chest.2022.02.007>.
- 712 51. Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, Mailyan A,
713 Manghi P, Scholz M, Thomas AM, Valles-Colomer M, Weingart G, Zhang Y, Zolfo M,
714 Huttenhower C, Franzosa EA, Segata N. 2021. Integrating taxonomic, functional, and
715 strain-level profiling of diverse microbial communities with biobakery 3. *Elife* 10.
- 716 52. Mall MA, Brugha R, Gartner S, Legg J, Moeller A, Mondejar-Lopez P, Prais D, Pressler
717 T, Ratjen F, Reix P, Robinson PD, Selvadurai H, Stehling F, Ahluwalia N, Arteaga-Solis
718 E, Bruinsma BG, Jennings M, Moskowitz SM, Noel S, Tian S, Weinstock TG, Wu P,
719 Wainwright CE, Davies JC. 2022. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor
720 in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del
721 and a Minimal Function Mutation A Phase 3b, Randomized, Placebo-controlled Study.
722 *Am J Respir Crit Care Med* 206:1361–1369.
- 723 53. Streibel C, Willers CC, Pusterla O, Bauman G, Stranzinger E, Brabant B, Bieri O, Curdy
724 M, Bullo M, Frauchiger BS, Korten I, Krüger L, Casaulta C, Ratjen F, Latzin P, Kieninger
725 E. 2023. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis
726 – a comprehensive assessment using lung clearance index, spirometry, and functional and
727 structural lung MRI. *Journal of Cystic Fibrosis* <https://doi.org/10.1016/j.jcf.2022.12.012>.
- 728 54. Jordan KD, Zemanick ET, Taylor-Cousar JL, Hoppe JE. 2023. Managing cystic fibrosis in
729 children aged 6-11 yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination
730 therapy. *Expert Rev Respir Med*. Taylor and Francis Ltd.
731 <https://doi.org/10.1080/17476348.2023.2179989>.
- 732 55. Kapouni N, Moustaki M, Douros K, Loukou I. 2023. Efficacy and Safety of Elexacaftor-
733 Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review. *Children*
734 10:554.
- 735 56. Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, Retsch-
736 Bogart G, Roesch E, Ahluwalia N, Chin A, Chu C, Lu M, Menon P, Waltz D, Weinstock
737 T, Zelazoski L, Davies JC, VX19-445-107 Study Group. 2023. Long-Term Safety and
738 Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥ 6 Years with Cystic

- 739 Fibrosis and At Least One F508del Allele: A Phase 3, Open-Label Clinical Trial. *Am J*
740 *Respir Crit Care Med* <https://doi.org/10.1164/rccm.202301-0021OC>.
- 741 57. Cornet M, Robin G, Ciciriello F, Bihoue T, Marguet C, Roy V, Lebourgeois M,
742 Chedeveigne F, Bonnel AS, Kelly M, Reix P, Lucidi V, Stoven V, Sermet-Gaudelus I.
743 2022. Profiling the response to lumacaftor-ivacaftor in children with cystic between
744 fibrosis and new insight from a French-Italian real-life cohort. *Pediatr Pulmonol*
745 <https://doi.org/10.1002/ppul.26123>.
- 746 58. Appelt D, Steinkamp G, Sieber S, Ellemunter H. 2023. Early and sustained improvements
747 of lung clearance index from two to sixteen weeks of elexacaftor/tezacaftor/ivacaftor
748 therapy in patients with cystic fibrosis—a real world study. *Front Pharmacol* 14.
- 749 59. Gramegna A, Majo F, Alicandro G, Leonardi G, Cristiani L, Amati F, Contarini M,
750 Aliberti S, Fiocchi AG, Blasi F. 2023. Heterogeneity of weight gain after initiation of
751 Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis. *Respir Res* 24.
- 752 60. Matamouros S, Hayden HS, Hager KR, Brittnacher MJ, Lachance K, Weiss EJ, Pope CE,
753 Imhaus AF, McNally CP, Borenstein E, Hoffman LR, Miller SI. 2018. Adaptation of
754 commensal proliferating *Escherichia coli* to the intestinal tract of young children with
755 cystic fibrosis. *Proc Natl Acad Sci U S A* 115:1605–1610.
- 756 61. Freitas MB De, Addison E, Moreira M, Tomio C, Maria Y, Moreno F, Daltoe FP, Barbosa
757 E, Neto NL, Buccigrossi V, Guarino A. 2018. Altered intestinal microbiota composition,
758 antibiotic therapy and intestinal inflammation in children and adolescents with cystic
759 fibrosis. *PLoS One* 13.
- 760 62. Duytschaever G, Huys G, Bekaert M, Boulanger L, De Boeck K, Vandamme P. 2013.
761 Dysbiosis of bifidobacteria and *Clostridium* cluster XIVa in the cystic fibrosis fecal
762 microbiota. *Journal of Cystic Fibrosis* 12:206–215.
- 763 63. Nielsen S, Needham B, Leach ST, Day AS, Jaffe A, Thomas T, Ooi CY. 2016. Disrupted
764 progression of the intestinal microbiota with age in children with cystic fibrosis. *Sci Rep*
765 6.
- 766 64. Debyser G, Mesuere B, Clement L, Van de Weygaert J, Van Hecke P, Duytschaever G,
767 Aerts M, Dawyndt P, De Boeck K, Vandamme P, Devreese B. 2016. Faecal proteomics: A
768 tool to investigate dysbiosis and inflammation in patients with cystic fibrosis. *Journal of*
769 *Cystic Fibrosis* 15:242–250.
- 770 65. Bernard R, Shilts MH, Strickland BA, Boone HH, Payne DC, Brown RF, Edwards K, Das
771 SR, Nicholson MR. 2023. The relationship between the intestinal microbiome and body
772 mass index in children with cystic fibrosis. *Journal of Cystic Fibrosis*
773 <https://doi.org/10.1016/j.jcf.2023.11.002>.
- 774 66. Hollister EB, Riehle K, Luna RA, Weidler EM, Rubio-Gonzales M, Mistretta TA, Raza S,
775 Doddapaneni H V., Metcalf GA, Muzny DM, Gibbs RA, Petrosino JF, Shulman RJ,
776 Versalovic J. 2015. Structure and function of the healthy pre-adolescent pediatric gut
777 microbiome. *Microbiome* 3:36.
- 778 67. Mehta RS, Abu-Ali GS, Drew DA, Lloyd-Price J, Subramanian A, Lochhead P, Joshi AD,
779 Ivey KL, Khalili H, Brown GT, Dulong C, Song M, Nguyen LH, Mallick H, Rimm EB,
780 IZard J, Huttenhower C, Chan AT. 2018. Stability of the human faecal microbiome in a
781 cohort of adult men. *Nat Microbiol* 3:347–355.
- 782 68. David LA, Materna AC, Friedman J, Campos-Baptista MI, Blackburn MC, Perrotta A,
783 Erdman SE, Alm EJ. 2014. Host lifestyle affects human microbiota on daily timescales.
784 *Genome Biol* 15.

- 785 69. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, Clemente
786 JC, Knight R, Heath AC, Leibel RL, Rosenbaum M, Gordon JI. 2013. The long-term
787 stability of the human gut microbiota. *Science* (1979) 341.
- 788 70. Yamada A, Komaki Y, Komaki F, Micic D, Zullo S, Sakuraba A. 2018. Risk of
789 gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-
790 analysis. *Lancet Oncol* 19:758–767.
- 791 71. Garg M, Leach ST, Coffey MJ, Katz T, Strachan R, Pang T, Needham B, Lui K, Ali F,
792 Day AS, Appleton L, Moeeni V, Jaffe A, Ooi CY. 2017. Age-dependent variation of fecal
793 calprotectin in cystic fibrosis and healthy children. *Journal of Cystic Fibrosis* 16:631–636.
- 794 72. Rumman N, Sultan M, El-Chammas K, Goh V, Salzman N, Quintero D, Werlin S. 2014.
795 Calprotectin in Cystic Fibrosis. *BMC Pediatr* 14.
- 796 73. Beaufils F, Mas E, Mittaine M, Addra M, Fayon M, Delhaes L, Clouzeau H, Galode F,
797 Lamireau T, Bui S, Enaud R. 2020. Increased Fecal Calprotectin Is Associated with
798 Worse Gastrointestinal Symptoms and Quality of Life Scores in Children with Cystic
799 Fibrosis. *J Clin Med* 9:4080.
- 800 74. Schwarzenberg SJ, Vu PT, Skalland M, Hoffman LR, Pope C, Gelfond D, Narkewicz MR,
801 Nichols DP, Heltshe SL, Donaldson SH, Frederick CA, Kelly A, Pittman JE, Ratjen F,
802 Rosenfeld M, Sagel SD, Solomon GM, Stalvey MS, Clancy JP, Rowe SM, Freedman SD.
803 2022. Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis:
804 Report of promise-GI. *Journal of Cystic Fibrosis* <https://doi.org/10.1016/j.jcf.2022.10.003>.
- 805 75. Mainz JG, Lester K, Elnazir B, Williamson M, McKone E, Cox D, Linnane B, Zagoya C,
806 Duckstein F, Barucha A, Davies JC, McNally P. 2023. Reduction in abdominal symptoms
807 (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment
808 with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥ 12 years – The
809 RECOVER study. *Journal of Cystic Fibrosis* <https://doi.org/10.1016/j.jcf.2023.10.001>.
- 810 76. Baldwin-Hunter BL, Rozenberg FD, Annavaajhala MK, Park H, DiMango EA, Keating
811 CL, Uhlemann A-C, Abrams JA. 2023. The gut microbiome, short chain fatty acids, and
812 related metabolites in cystic fibrosis patients with and without colonic adenomas. *Journal*
813 *of Cystic Fibrosis* <https://doi.org/10.1016/j.jcf.2023.01.013>.
- 814 77. Miragoli F, Federici S, Ferrari S, Minuti A, Rebecchi A, Bruzzese E, Buccigrossi V,
815 Guarino A, Callegari ML. 2017. Impact of cystic fibrosis disease on archaea and bacteria
816 composition of gut microbiota. *FEMS Microbiol Ecol* 93.
- 817 78. Burke DG, Fouhy F, Harrison MJ, Rea MC, Cotter PD, O’Sullivan O, Stanton C, Hill C,
818 Shanahan F, Plant BJ, Ross RP. 2017. The altered gut microbiota in adults with cystic
819 fibrosis. *BMC Microbiol* 17:1–11.
- 820 79. Rivera-Chávez F, Lopez CA, Bäumlner AJ. 2017. Oxygen as a driver of gut dysbiosis. *Free*
821 *Radic Biol Med*. Elsevier Inc. <https://doi.org/10.1016/j.freeradbiomed.2016.09.022>.
- 822 80. Shah YM. 2016. The role of hypoxia in intestinal inflammation. *Mol Cell Pediatr* 3.
- 823 81. Rigottier-Gois L. 2013. Dysbiosis in inflammatory bowel diseases: The oxygen
824 hypothesis. *ISME Journal* <https://doi.org/10.1038/ismej.2013.80>.
- 825 82. López-Causapé C, Rojo-Molinero E, MacIà MD, Oliver A. 2015. The problems of
826 antibiotic resistance in cystic fibrosis and solutions. *Expert Rev Respir Med*. Expert
827 Reviews Ltd. <https://doi.org/10.1586/17476348.2015.995640>.
- 828 83. Taylor SL, Leong LEX, Sims SK, Keating RL, Papanicolaou LE, Richard A, Mobegi FM,
829 Wesselingh S, Burr LD, Rogers GB. 2021. The cystic fibrosis gut as a potential source of
830 multidrug resistant pathogens. *Journal of Cystic Fibrosis* 20:413–420.

- 831 84. Fredriksen S, de Warle S, van Baarlen P, Boekhorst J, Wells JM. 2023. Resistome
832 expansion in disease-associated human gut microbiomes. *Microbiome* 11:166.
833 85. Patel D, Mathews S, van Unen V, Chan JE, Al-Hammadi N, Borowitz D, Gelfond D,
834 Sellers ZM. 2022. Impaired distal colonic pH in adults with cystic fibrosis. *Journal of*
835 *Cystic Fibrosis* <https://doi.org/10.1016/j.jcf.2022.12.011>.
836 86. Gelfond D, Heltshe S, Ma C, Rowe SM, Frederick C, Uluer A, Sicilian L, Konstan M,
837 Tullis E, Roach RNC, Griffin K, Joseloff E, Borowitz D. 2017. Impact of CFTR
838 modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis
839 and the G551D mutation. *Clin Transl Gastroenterol* 8.

840

841 **TABLES AND FIGURES**

842 **Table 1. Cohort Baseline Details**

843 **Figure 1. Study Schematic, Timeline, and Clinical Improvement after ELX/TEZ/IVA**

844 **Figure 2. Microbiome Diversity Increases After ELX/TEZ/IVA**

845 **Figure 3. Intestinal Carriage of Antibiotic Resistance Genes**

846 **Figure 4. Specific Microbial Taxonomic Changes after ELX/TEZ/IVA**

847 **Figure 5. Intestinal Inflammation Decreases after ELX/TEZ/IVA and Microbiome**

848 **Functional Changes**

849 **Supplementary Figure 1. Clinical Data Across the Four-Timepoints**

850 **Supplementary Figure 2. Microbiome Alpha Diversity and Beta Diversity**

851 **Supplementary Figure 3. Prior CFTR Modulators and Microbiome Diversity**

852 **Supplementary Figure 4. Reduced Abundance of Intestinal Antibiotic Resistance Genes**

853 **Supplementary Figure 5. Respiratory Taxa in Stool Samples**

854 **Supplementary Figure 6. Fecal Calprotectin at Four-Timepoints and Differentially**

855 **Abundant KEGG Orthology Groups**

856 **Supplementary Figure 7. Differentially Abundant MetaCyc Pathways**

857 **Supplementary Table S1. Complete Metadata**

858 **Supplementary Table S2. Species MaAsLin2 Results**

859 **Supplementary Table S3. Differentially Abundant Species with Respect to ELX/TEZ/IVA**

860 **Supplementary Table S4. MaAsLin2 Results Across Taxonomic Levels**

861 **Supplementary Table S5. MaAsLin2 Results of Antibiotic Resistance Genes**

862 **Supplementary Table S6. MaAsLin2 Results of KEGG Orthology Groups**

863 **Supplementary Table S7. Differentially Abundant KEGG Orthology Groups with Respect**

864 **to ELX/TEZ/IVA**

865 **Supplementary Table S8. MaAsLin2 Results of MetaCyc Pathways**

866 **Supplementary Table S9. Differentially Abundant MetaCyc Pathways with Respect to**

867 **ELX/TEZ/IVA**

868 **Supplementary Table S10. Stratified Taxonomic Output of Differentially Abundant KEGG**
869 **Orthology Groups**

870 **Supplementary Dataset 1. Compiled Metadata and Metagenomic Results**

871

872 **FIGURE LEGENDS**

873

874 **Figure 1. Study Schematic, Timeline, and Clinical Improvement after ELX/TEZ/IVA.**

875 **A)** Overview of study procedure and analyses. **B)** Timeline illustrating the four timepoints. Day 0
876 is depicted as the day of ELX/TEZ/IVA initiation. A total of 114 samples were collected from 39
877 unique patients, of which 53 samples were before ELX/TEZ/IVA treatment and 61 samples after
878 treatment. **C-E)** Depictions of clinical data before and after ELX/TEZ/IVA; **(C)** ppFEV1, **(D)** BMI
879 percentile, **(E)** antibiotic days per 6-months. Each dot represents the clinical data associated
880 with a stool sample. P values calculated by Wilcoxon rank-sum test.

881

882 **Figure 2. Microbiome Diversity and Intestinal Carriage of Antibiotic Resistance Genes.**

883 **A)** Phylum level relative abundance for samples collected before (samples=53) and after
884 (samples=61) ELX/TEZ/IVA. Samples are organized by the relative abundance of the phylum
885 Firmicutes. **B-C)** Alpha diversity before and after ELX/TEZ/IVA. Shannon Index calculated with
886 the R package vegan using species abundance table from Metaphlan4. Microbial richness
887 represents the number of unique species per sample. Each dot represents a stool sample
888 (samples=114). P values calculated by Wilcoxon rank-sum test. **D-E)** Alpha diversity between
889 samples with and without recent antibiotic exposure. Recent antibiotic exposure categorized as
890 any systemic antibiotic within the past 6-months. Shannon Index calculated with the R package
891 vegan using species abundance table from MetaPhlan4. Microbial richness represents the
892 number of unique species per sample. Each dot represents a stool sample (samples=114). P
893 values calculated by Wilcoxon rank-sum test.

894

895 **Figure 3. A)** Antibiotic resistance gene (ARG) abundance (RPKM) before and after
896 ELX/TEZ/IVA. ARGs were profiled using ShortBRED and the Comprehensive Antibiotic
897 Resistance Database (CARD). Each dot represents a stool sample (samples=114). P values
898 calculated by Wilcoxon rank-sum test. **B)** ARG abundance (RPKM) by class of antibiotic to
899 which they confer resistance. Abundance values of zero are plotted on the vertical axis. P
900 values calculated by Wilcoxon signed-rank test.

901

902 **Figure 4. Specific Microbial Taxonomic Changes after ELX/TEZ/IVA.**

903 **A)** Differentially abundant species before and after ELX/TEZ/IVA. The results are depicted with
904 significance ($-\log_{10}$ of the FDR) (Y axis) vs. $\log_2(\text{FoldChange})$. MaAsLin2 multivariable
905 association modeling was implemented in R, using ELX/TEZ/IVA status, age, and recent
906 antibiotics as fixed effects in the model. Participant ID was used as a random effect. Horizontal
907 dashed line depicts FDR=0.1. Species reaching statistical significance (FDR \leq 0.10) are
908 highlighted in solid colors whereas other species are gray. **B)** Species of interest from
909 differential abundance testing before and after ELX/TEZ/IVA. Vertical axis is \log_{10} transformed.
910 MaAsLin2 FDR is depicted. Zero values are plotted on the horizontal axes. The percentage of
911 samples for which the relative abundance was zero is depicted below the graph.

912

913 **Figure 5. Intestinal Inflammation Decreases after ELX/TEZ/IVA and Microbiome**

914 **Functional Changes. A)** Fecal calprotectin before and after ELX/TEZ/IVA. Each dot represents
915 a stool sample (samples=114). P values calculated by Wilcoxon rank-sum test. **B-C)** Microbial
916 dysbiosis index (MD-INDEX) before and after ELX/TEZ/IVA (**B**) or between samples with and
917 without recent antibiotic exposure (**C**). MD-index calculated as the \log_{10} ratio of species
918 positively/negatively correlated with new onset pediatric Crohn's disease (44). Each dot
919 represents a stool sample (samples=114). P values calculated by Wilcoxon rank-sum test. **D)**
920 Differentially abundant KEGG orthologs following MaAsLin2 multivariable association modeling,
921 using ELX/TEZ/IVA status, age, and recent antibiotics as fixed effects in the model. Participant
922 ID was used as a random effect. Horizontal dashed line depicts FDR=0.25. **E)** Subset of
923 differentially abundant MetaCyc pathways following MaAsLin2 multivariable association
924 modeling, using ELX/TEZ/IVA status, age, and recent antibiotics as fixed effects in the model.
925 Only pathways with FDR<0.25 are depicted.

926

927 **Supplementary Figure S1. A-D)** Clinical metadata vs. timepoint; **(A)** ppFEV1, **(B)** BMI
928 percentile, **(C)** weight percentile, and **(D)** height percentile. Each dot represents the clinical data
929 associated with a stool sample. Red line indicates the mean, and gray lines represent individual
930 patients. P values calculated by Wilcoxon signed-rank test.

931

932 **Supplementary Figure S2. A-B)** Alpha diversity vs. timepoint. Shannon Index **(A)** calculated
933 with the R package vegan using species abundance table from Metaphlan4. Microbial richness
934 **(B)** represents the number of unique species per sample. Each dot represents a stool sample
935 (samples=114). P values calculated by Wilcoxon signed-rank test. **C)** Principal component

936 analysis of Bray-Curtis distances before and after ELX/TEZ/IVA. Bray-Curtis distance matrix
937 computed with vegan. PERMANOVA and PERMDISP computed by the vegan package with the
938 functions adonis2 and betadisp, respectively. Ellipse depicts the 95% confidence level. **D)**
939 Principal component analysis of weighted UniFrac distances before and after ELX/TEZ/IVA.
940 Weighted UniFrac computed with MetaPhlAn4 R script. PERMANOVA and PERMDISP
941 computed by the vegan package with the functions adonis2 and betadisp, respectively. Ellipse
942 depicts the 95% confidence level. **E)** Principal component analysis of the Bray-Curtis distances
943 between samples with and without recent antibiotic exposure. Distance matrix generated by the
944 R package vegan using the MetaPhlAn4 species table. PERMANOVA and PERMDISP
945 computed in vegan with the functions adonis2 and betadisp, respectively. Ellipse depicts the
946 95% confidence level.

947
948 **Supplementary Figure S3. A-B)** Diversity metrics of pre-ELX/TEZ/IVA samples (samples=53
949 total). Samples are grouped by whether the subject was receiving another CFTR modulator at
950 the time of sample collection (Yes=8, No=45). **C-D)** Diversity metrics of pre-ELX/TEZ/IVA
951 samples (samples=53) compared to post-ELX/TEZ/IVA samples (samples=61). Post-
952 ELX/TEZ/IVA samples were segregated by whether the subject had previously received any
953 other CFTR modulator (Yes=20 samples, No=41 samples). Shannon Index calculated with the
954 R package vegan using species abundance table from MetaPhlAn4. Microbial richness
955 represents the number of unique species per sample. P values calculated by Wilcoxon rank-
956 sum test.

957
958 **Supplementary Figure S4. A)** Cumulative antibiotic days per 6-months prior to stool sample
959 collection. P values calculated by Wilcoxon signed-rank test. **B)** ARG richness (unique genes)
960 before and after ELX/TEZ/IVA. ARGs were profiled using ShortBRED and the Comprehensive
961 Antibiotic Resistance Database (CARD). Each dot represents a stool sample (samples=114). P
962 values calculated by Wilcoxon rank-sum test. **C)** Cumulative relative abundance (RPKM) of
963 ARGs conferring resistance to peptide antibiotics. P values calculated by Wilcoxon rank-sum
964 test. **D)** Relative abundance (RPKM) of the most prevalent ARGs conferring resistance to
965 peptide antibiotics. MaAsLin2 FDR is depicted. **E)** Cumulative relative abundance (RPKM) of
966 ARGs conferring resistance to other antibiotics. P values calculated by Wilcoxon rank-sum test.
967 **F)** Relative abundance (RPKM) of the most prevalent ARGs conferring resistance to other
968 antibiotics. MaAsLin2 FDR is depicted.

969

970 **Supplementary Figure S5. A)** *Roseburia faecis* relative abundance between samples with and
971 without recent antibiotic exposure. Each dot represents a stool sample (samples=114).
972 MaAsLin2 FDR is depicted. **B)** Relative abundance of respiratory genera in stool samples
973 before and after ELX/TEZ/IVA. Each dot represents a stool sample (samples=114). MaAsLin2
974 FDR is depicted. Vertical axis is log₁₀ transformed. Zero values are plotted on the horizontal
975 axes.






976

977 **Supplementary Figure S6. A)** Fecal calprotectin (μg/g) vs. study timepoint. Red line indicates
978 the mean, and gray lines represent individual patients. P values calculated by Wilcoxon signed-
979 rank test. **B)** Differentially abundant oxidative phosphorylation KEGG orthology (KO) groups
980 from MaAsLin2 (FDR<0.25). Groups correspond to red points in Fig. 5A. log₂(FoldChange),
981 which is equivalent to MaAsLin2 coefficient, is depicted. **C)** Taxonomic stratification of
982 differentially abundant oxidative phosphorylation KO groups. KO groups correspond to groups in
983 panel A.


984

985 **Supplementary Figure S7.** Differentially abundant MetaCyc pathways following MaAsLin2
986 multivariable association modeling, using ELX/TEZ/IVA status, age, and recent antibiotics as
987 fixed effects in the model. Only pathways with FDR<0.25 are depicted.


It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).




A




B




C





D



E




It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).




A


It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).




B




A




B




C








D



E









Supplemental Figure 3

Before ELX/TEZ/IVA

53 total samples

45 modulator naïve samples

8 samples on another modulator





After ELX/TEZ/IVA


61 total samples

41 samples from subjects without prior modulator use


20 samples from subjects with prior modulator use




It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).






A



B





Supplemental Figure 7

It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

MetaCyc Pathway

